Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative short-course pancreatin for pancreatic cancer with obstructed and dilated pancreatic duct
ChiCTR2400083347Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Apr 2024
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Insulin and Analogs → Hormones & Growth Factors → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of pancreatin in pancreatic cancer (PC) (3 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoints: Serological inflammatory markers, Pathological pancreatitis score and 1 more. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
pancreatin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2400083347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083347.